Information Provided By: 
Fly News Breaks for October 20, 2015
TEVA, AGN
Oct 20, 2015 | 07:43 EDT
Cowen believes Allergan's (AGN) pipeline is underappreciated as it likely has 2 drugs with $1B+ potential. The firm also said its capital allocation remains the biggest potential lever and the company remains well positioned with the capital to come from Teva (TEVA) and the broader asset price correction in biopharma. Cowen reiterated its Outperform rating and $400 price target on Allergan shares.
News For AGN;TEVA From the Last 2 Days
There are no results for your query AGN;TEVA
